DRMA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Dermata Therapeutics Inc (DRMA) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits weak financial performance, bearish technical indicators, and lacks positive trading signals or catalysts. Additionally, there is no significant insider or hedge fund activity, and no recent congress trading data to support a buy decision.
The technical indicators for DRMA are bearish. The MACD histogram is negative and contracting, the RSI is neutral at 39.686, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 1.162 and resistance at 2.029.
NULL identified. There are no significant trading trends, insider activity, or hedge fund interest. No AI Stock Picker or SwingMax signals are present.
The stock's technical indicators are bearish, and there is no recent congress trading data or significant news to support a positive outlook.
In Q3 2025, the company's revenue remained stagnant at 0, net income dropped by -46.68% YoY to -1,691,989, and EPS fell by -91.92% YoY to -1.65. Gross margin remained at 0 with no growth.
No data available for analyst ratings or price target changes.
